Latest News - Phase 3/4 Trials

Tuesday, December 05, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications

Investigational Neurotoxin Achieves 6-Month Duration in Phase 3: Revance

Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivota…

Read the full story

Thursday, April 06, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Galderma

Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studies

Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that…

Read the full story